CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
Jiyun Lee, Joon Ho Shim, Woong-Yang Park, Hee Kyung Kim, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Cancer Research and Treatment. 2019;51(1):408-412.   Published online 2018 May 23    DOI: https://doi.org/10.4143/crt.2018.138

Excel Download

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
Cancer Research and Treatment. 2019;51(1):408-412   Crossref logo
Link1 Link2 Link3

Computational methods for the analysis and prediction of drug resistance in EGFR-mutated non-small cell lung cancer patients
. 2021;   Crossref logo
Link1

Computational methods for the analysis and prediction of drug resistance in EGFR-mutated non-small cell lung cancer patients
. 2021;   Crossref logo
Link1

Osimertinib
Reactions Weekly. 2021;1836(1):619-619   Crossref logo
Link1 Link2 Link3

A Case Report of Successful treatment with Crizotinib to overcome resistance to Osimertinib in an EGFR mutated non small cell lung cancer patient harboring an acquired MET Exon 14 mutation.
Clinical Lung Cancer. 2021;   Crossref logo
Link1 Link2

Challenges in the Management of EGFR-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors
Oncology. 2014;87(2):83-94   Crossref logo
Link1 Link2

REBIOPSY IN NON-SMALL CELL LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI
Respirology. 2017;22:242-242   Crossref logo
Link1 Link2

Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report
Lung Cancer. 2017;114:68-69   Crossref logo
Link1 Link2

Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3 -mutation, localized transformation to EGFR -mutated SCLC, and acquired T790M EGFR -mutation
Lung Cancer. 2017;113:14-17   Crossref logo
Link1 Link2

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
Nature Communications. 2017;8(1):   Crossref logo
Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.